HealthCare Royalty and Blue Owl Announce $250M Debt Financing with TG Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
TG Therapeutics (TGTX) PT Raised to $30 at JPMorgan
August 7, 2024 6:17 AM EDTJPMorgan analyst Eric Joseph raised the price target on TG Therapeutics (NASDAQ: TGTX) to $30.00 (from $26.00) while maintaining a Overweight rating.
The analyst comments "Following TGs 2Q results and conference call we are updating our model, with takeaways from the call... More
